Copyright Reports & Markets. All rights reserved.

Global T Cell Surface Glycoprotein CD3 Epsilon Chain Market Insights, Forecast to 2025

Request for Sample of this report
Buy now

Table of Contents

    1 Study Coverage

    • 1.1 T Cell Surface Glycoprotein CD3 Epsilon Chain Product
    • 1.2 Market Segments
    • 1.3 Key Manufacturers Covered
    • 1.4 Market by Type
      • 1.4.1 Global T Cell Surface Glycoprotein CD3 Epsilon Chain Market Size Growth Rate by Product
      • 1.4.2 ND-007
      • 1.4.3 Foralumab
      • 1.4.4 Coltelizumab
      • 1.4.5 AVA-002
      • 1.4.6 Others
    • 1.5 Market by End User
      • 1.5.1 Global T Cell Surface Glycoprotein CD3 Epsilon Chain Market Size Growth Rate by End User
      • 1.5.2 Autoimmune Disorders
      • 1.5.3 Hepatitis B
      • 1.5.4 Multiple Sclerosis
      • 1.5.5 Prostate Cancer
      • 1.5.6 Others
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Executive Summary

    • 2.1 Global T Cell Surface Glycoprotein CD3 Epsilon Chain Market Size
      • 2.1.1 Global T Cell Surface Glycoprotein CD3 Epsilon Chain Revenue 2014-2025
      • 2.1.2 Global T Cell Surface Glycoprotein CD3 Epsilon Chain Sales 2014-2025
    • 2.2 T Cell Surface Glycoprotein CD3 Epsilon Chain Growth Rate by Regions
      • 2.2.1 Global T Cell Surface Glycoprotein CD3 Epsilon Chain Sales by Regions
      • 2.2.2 Global T Cell Surface Glycoprotein CD3 Epsilon Chain Revenue by Regions

    3 Breakdown Data by Manufacturers

    • 3.1 T Cell Surface Glycoprotein CD3 Epsilon Chain Sales by Manufacturers
      • 3.1.1 T Cell Surface Glycoprotein CD3 Epsilon Chain Sales by Manufacturers
      • 3.1.2 T Cell Surface Glycoprotein CD3 Epsilon Chain Sales Market Share by Manufacturers
      • 3.1.3 Global T Cell Surface Glycoprotein CD3 Epsilon Chain Market Concentration Ratio (CR5 and HHI)
    • 3.2 T Cell Surface Glycoprotein CD3 Epsilon Chain Revenue by Manufacturers
      • 3.2.1 T Cell Surface Glycoprotein CD3 Epsilon Chain Revenue by Manufacturers (2014-2019)
      • 3.2.2 T Cell Surface Glycoprotein CD3 Epsilon Chain Revenue Share by Manufacturers (2014-2019)
    • 3.3 T Cell Surface Glycoprotein CD3 Epsilon Chain Price by Manufacturers
    • 3.4 T Cell Surface Glycoprotein CD3 Epsilon Chain Manufacturing Base Distribution, Product Types
      • 3.4.1 T Cell Surface Glycoprotein CD3 Epsilon Chain Manufacturers Manufacturing Base Distribution, Headquarters
      • 3.4.2 Manufacturers T Cell Surface Glycoprotein CD3 Epsilon Chain Product Type
      • 3.4.3 Date of International Manufacturers Enter into T Cell Surface Glycoprotein CD3 Epsilon Chain Market
    • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Product

    • 4.1 Global T Cell Surface Glycoprotein CD3 Epsilon Chain Sales by Product
    • 4.2 Global T Cell Surface Glycoprotein CD3 Epsilon Chain Revenue by Product
    • 4.3 T Cell Surface Glycoprotein CD3 Epsilon Chain Price by Product

    5 Breakdown Data by End User

    • 5.1 Overview
    • 5.2 Global T Cell Surface Glycoprotein CD3 Epsilon Chain Breakdown Data by End User

    6 North America

    • 6.1 North America T Cell Surface Glycoprotein CD3 Epsilon Chain by Countries
      • 6.1.1 North America T Cell Surface Glycoprotein CD3 Epsilon Chain Sales by Countries
      • 6.1.2 North America T Cell Surface Glycoprotein CD3 Epsilon Chain Revenue by Countries
      • 6.1.3 United States
      • 6.1.4 Canada
      • 6.1.5 Mexico
    • 6.2 North America T Cell Surface Glycoprotein CD3 Epsilon Chain by Product
    • 6.3 North America T Cell Surface Glycoprotein CD3 Epsilon Chain by End User

    7 Europe

    • 7.1 Europe T Cell Surface Glycoprotein CD3 Epsilon Chain by Countries
      • 7.1.1 Europe T Cell Surface Glycoprotein CD3 Epsilon Chain Sales by Countries
      • 7.1.2 Europe T Cell Surface Glycoprotein CD3 Epsilon Chain Revenue by Countries
      • 7.1.3 Germany
      • 7.1.4 France
      • 7.1.5 UK
      • 7.1.6 Italy
      • 7.1.7 Russia
    • 7.2 Europe T Cell Surface Glycoprotein CD3 Epsilon Chain by Product
    • 7.3 Europe T Cell Surface Glycoprotein CD3 Epsilon Chain by End User

    8 Asia Pacific

    • 8.1 Asia Pacific T Cell Surface Glycoprotein CD3 Epsilon Chain by Countries
      • 8.1.1 Asia Pacific T Cell Surface Glycoprotein CD3 Epsilon Chain Sales by Countries
      • 8.1.2 Asia Pacific T Cell Surface Glycoprotein CD3 Epsilon Chain Revenue by Countries
      • 8.1.3 China
      • 8.1.4 Japan
      • 8.1.5 Korea
      • 8.1.6 India
      • 8.1.7 Australia
      • 8.1.8 Indonesia
      • 8.1.9 Malaysia
      • 8.1.10 Philippines
      • 8.1.11 Thailand
      • 8.1.12 Vietnam
      • 8.1.13 Singapore
    • 8.2 Asia Pacific T Cell Surface Glycoprotein CD3 Epsilon Chain by Product
    • 8.3 Asia Pacific T Cell Surface Glycoprotein CD3 Epsilon Chain by End User

    9 Central & South America

    • 9.1 Central & South America T Cell Surface Glycoprotein CD3 Epsilon Chain by Countries
      • 9.1.1 Central & South America T Cell Surface Glycoprotein CD3 Epsilon Chain Sales by Countries
      • 9.1.2 Central & South America T Cell Surface Glycoprotein CD3 Epsilon Chain Revenue by Countries
      • 9.1.3 Brazil
    • 9.2 Central & South America T Cell Surface Glycoprotein CD3 Epsilon Chain by Product
    • 9.3 Central & South America T Cell Surface Glycoprotein CD3 Epsilon Chain by End User

    10 Middle East and Africa

    • 10.1 Middle East and Africa T Cell Surface Glycoprotein CD3 Epsilon Chain by Countries
      • 10.1.1 Middle East and Africa T Cell Surface Glycoprotein CD3 Epsilon Chain Sales by Countries
      • 10.1.2 Middle East and Africa T Cell Surface Glycoprotein CD3 Epsilon Chain Revenue by Countries
      • 10.1.3 GCC Countries
      • 10.1.4 Turkey
      • 10.1.5 Egypt
      • 10.1.6 South Africa
    • 10.2 Middle East and Africa T Cell Surface Glycoprotein CD3 Epsilon Chain by Product
    • 10.3 Middle East and Africa T Cell Surface Glycoprotein CD3 Epsilon Chain by End User

    11 Company Profiles

    • 11.1 Amgen Inc
      • 11.1.1 Amgen Inc Company Details
      • 11.1.2 Company Business Overview
      • 11.1.3 Amgen Inc T Cell Surface Glycoprotein CD3 Epsilon Chain Sales, Revenue and Gross Margin (2014-2019)
      • 11.1.4 Amgen Inc T Cell Surface Glycoprotein CD3 Epsilon Chain Products Offered
      • 11.1.5 Amgen Inc Recent Development
    • 11.2 Celgene Corp
      • 11.2.1 Celgene Corp Company Details
      • 11.2.2 Company Business Overview
      • 11.2.3 Celgene Corp T Cell Surface Glycoprotein CD3 Epsilon Chain Sales, Revenue and Gross Margin (2014-2019)
      • 11.2.4 Celgene Corp T Cell Surface Glycoprotein CD3 Epsilon Chain Products Offered
      • 11.2.5 Celgene Corp Recent Development
    • 11.3 F. Hoffmann-La Roche Ltd
      • 11.3.1 F. Hoffmann-La Roche Ltd Company Details
      • 11.3.2 Company Business Overview
      • 11.3.3 F. Hoffmann-La Roche Ltd T Cell Surface Glycoprotein CD3 Epsilon Chain Sales, Revenue and Gross Margin (2014-2019)
      • 11.3.4 F. Hoffmann-La Roche Ltd T Cell Surface Glycoprotein CD3 Epsilon Chain Products Offered
      • 11.3.5 F. Hoffmann-La Roche Ltd Recent Development
    • 11.4 GlaxoSmithKline Plc
      • 11.4.1 GlaxoSmithKline Plc Company Details
      • 11.4.2 Company Business Overview
      • 11.4.3 GlaxoSmithKline Plc T Cell Surface Glycoprotein CD3 Epsilon Chain Sales, Revenue and Gross Margin (2014-2019)
      • 11.4.4 GlaxoSmithKline Plc T Cell Surface Glycoprotein CD3 Epsilon Chain Products Offered
      • 11.4.5 GlaxoSmithKline Plc Recent Development
    • 11.5 MacroGenics Inc
      • 11.5.1 MacroGenics Inc Company Details
      • 11.5.2 Company Business Overview
      • 11.5.3 MacroGenics Inc T Cell Surface Glycoprotein CD3 Epsilon Chain Sales, Revenue and Gross Margin (2014-2019)
      • 11.5.4 MacroGenics Inc T Cell Surface Glycoprotein CD3 Epsilon Chain Products Offered
      • 11.5.5 MacroGenics Inc Recent Development
    • 11.6 Meridigen Biotech Co Ltd
      • 11.6.1 Meridigen Biotech Co Ltd Company Details
      • 11.6.2 Company Business Overview
      • 11.6.3 Meridigen Biotech Co Ltd T Cell Surface Glycoprotein CD3 Epsilon Chain Sales, Revenue and Gross Margin (2014-2019)
      • 11.6.4 Meridigen Biotech Co Ltd T Cell Surface Glycoprotein CD3 Epsilon Chain Products Offered
      • 11.6.5 Meridigen Biotech Co Ltd Recent Development
    • 11.7 Numab Innovation AG
      • 11.7.1 Numab Innovation AG Company Details
      • 11.7.2 Company Business Overview
      • 11.7.3 Numab Innovation AG T Cell Surface Glycoprotein CD3 Epsilon Chain Sales, Revenue and Gross Margin (2014-2019)
      • 11.7.4 Numab Innovation AG T Cell Surface Glycoprotein CD3 Epsilon Chain Products Offered
      • 11.7.5 Numab Innovation AG Recent Development
    • 11.8 SYNIMMUNE GmbH
      • 11.8.1 SYNIMMUNE GmbH Company Details
      • 11.8.2 Company Business Overview
      • 11.8.3 SYNIMMUNE GmbH T Cell Surface Glycoprotein CD3 Epsilon Chain Sales, Revenue and Gross Margin (2014-2019)
      • 11.8.4 SYNIMMUNE GmbH T Cell Surface Glycoprotein CD3 Epsilon Chain Products Offered
      • 11.8.5 SYNIMMUNE GmbH Recent Development
    • 11.9 Tiziana Life Sciences Plc
      • 11.9.1 Tiziana Life Sciences Plc Company Details
      • 11.9.2 Company Business Overview
      • 11.9.3 Tiziana Life Sciences Plc T Cell Surface Glycoprotein CD3 Epsilon Chain Sales, Revenue and Gross Margin (2014-2019)
      • 11.9.4 Tiziana Life Sciences Plc T Cell Surface Glycoprotein CD3 Epsilon Chain Products Offered
      • 11.9.5 Tiziana Life Sciences Plc Recent Development

    12 Future Forecast

    • 12.1 T Cell Surface Glycoprotein CD3 Epsilon Chain Market Forecast by Regions
      • 12.1.1 Global T Cell Surface Glycoprotein CD3 Epsilon Chain Sales Forecast by Regions 2019-2025
      • 12.1.2 Global T Cell Surface Glycoprotein CD3 Epsilon Chain Revenue Forecast by Regions 2019-2025
    • 12.2 T Cell Surface Glycoprotein CD3 Epsilon Chain Market Forecast by Product
      • 12.2.1 Global T Cell Surface Glycoprotein CD3 Epsilon Chain Sales Forecast by Product 2019-2025
      • 12.2.2 Global T Cell Surface Glycoprotein CD3 Epsilon Chain Revenue Forecast by Product 2019-2025
    • 12.3 T Cell Surface Glycoprotein CD3 Epsilon Chain Market Forecast by End User
    • 12.4 North America T Cell Surface Glycoprotein CD3 Epsilon Chain Forecast
    • 12.5 Europe T Cell Surface Glycoprotein CD3 Epsilon Chain Forecast
    • 12.6 Asia Pacific T Cell Surface Glycoprotein CD3 Epsilon Chain Forecast
    • 12.7 Central & South America T Cell Surface Glycoprotein CD3 Epsilon Chain Forecast
    • 12.8 Middle East and Africa T Cell Surface Glycoprotein CD3 Epsilon Chain Forecast

    13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

    • 13.1 Market Opportunities and Drivers
    • 13.2 Market Challenges
    • 13.3 Market Risks/Restraints
    • 13.4 Macroscopic Indicators

    14 Value Chain and Sales Channels Analysis

    • 14.1 Value Chain Analysis
    • 14.2 T Cell Surface Glycoprotein CD3 Epsilon Chain Customers
    • 14.3 Sales Channels Analysis
      • 14.3.1 Sales Channels
      • 14.3.2 Distributors

    15 Research Findings and Conclusion

      16 Appendix

      • 16.1 Research Methodology
        • 16.1.1 Methodology/Research Approach
        • 16.1.2 Data Source
      • 16.2 Author Details

      The global T Cell Surface Glycoprotein CD3 Epsilon Chain market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the T Cell Surface Glycoprotein CD3 Epsilon Chain market based on company, product type, end user and key regions.

      This report studies the global market size of T Cell Surface Glycoprotein CD3 Epsilon Chain in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of T Cell Surface Glycoprotein CD3 Epsilon Chain in these regions.
      This research report categorizes the global T Cell Surface Glycoprotein CD3 Epsilon Chain market by top players/brands, region, type and end user. This report also studies the global T Cell Surface Glycoprotein CD3 Epsilon Chain market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

      The following manufacturers are covered in this report, with sales, revenue, market share for each company:
      Amgen Inc
      Celgene Corp
      F. Hoffmann-La Roche Ltd
      GlaxoSmithKline Plc
      MacroGenics Inc
      Meridigen Biotech Co Ltd
      Numab Innovation AG
      SYNIMMUNE GmbH
      Tiziana Life Sciences Plc

      Market size by Product
      ND-007
      Foralumab
      Coltelizumab
      AVA-002
      Others
      Market size by End User
      Autoimmune Disorders
      Hepatitis B
      Multiple Sclerosis
      Prostate Cancer
      Others

      Market size by Region
      North America
      United States
      Canada
      Mexico
      Asia-Pacific
      China
      India
      Japan
      South Korea
      Australia
      Indonesia
      Singapore
      Malaysia
      Philippines
      Thailand
      Vietnam
      Europe
      Germany
      France
      UK
      Italy
      Spain
      Russia
      Central & South America
      Brazil
      Rest of Central & South America
      Middle East & Africa
      GCC Countries
      Turkey
      Egypt
      South Africa

      The study objectives of this report are:
      To study and analyze the global T Cell Surface Glycoprotein CD3 Epsilon Chain market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
      To understand the structure of T Cell Surface Glycoprotein CD3 Epsilon Chain market by identifying its various subsegments.
      To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
      Focuses on the key global T Cell Surface Glycoprotein CD3 Epsilon Chain companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
      To project the value and sales volume of T Cell Surface Glycoprotein CD3 Epsilon Chain submarkets, with respect to key regions.
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

      In this study, the years considered to estimate the market size of T Cell Surface Glycoprotein CD3 Epsilon Chain are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      This report includes the estimation of market size for value (million US$) and volume (K Pcs). Both top-down and bottom-up approaches have been used to estimate and validate the market size of T Cell Surface Glycoprotein CD3 Epsilon Chain market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now